Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute Effects of 2C-B vs MDMA and Psilocybin in Healthy Subjects
NCT05523401Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 4-bromo-2,5-dimethoxyphenethylamine (6 arms), sponsored by University Hospital Basel. Primary endpoint: Acute subjective effects I at 18 months. Started Aug 2023; status: completed.
02
Drugs
4-bromo-2,5-dimethoxyphenethylamine
Beyond the preview
Go deeper on NCT05523401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523401.